Today Stories

Acquisition Will Enhance End-to-End Global Healthcare Logistics Capabilities and Expand Scale and Expertise in Europe and Latin America LONDON, August 8, 2022 – UPS (NYSE: UPS) today announced plans to acquire Bomi Group, an industry-leading multinational healthcare logistics provider. The transaction will add temperature-controlled facilities in 14 countries and nearly 3,000 highly-skilled Bomi Group team members to the UPS Healthcare network in Europe and Latin America. “As a leading global healthcare logistics company, Bomi enhances our portfolio of services and accelerates our journey to become the number one provider of complex healthcare logistics,” said EVP and President of UPS International, Healthcare and Supply Chain Solutions Kate Gutmann. “UPS Healthcare and Bomi Group employee…

$76 million investment increases the site’s capacity to produce critical raw materials used in the development and manufacturing of vaccines and biologic therapies GRAND ISLAND, N.Y., Aug. 4, 2022 – To meet increasing global demand for cell culture media used in the manufacturing of new vaccines and biologics, Thermo Fisher Scientific has expanded its dry powder media manufacturing facility in Grand Island, New York. With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies. The Grand Island expansion is part of Thermo Fisher’s $650 million multi-…

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million, consisting of approximately $100 million in cash, and up to $70 million in future milestone payments. Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. “We…

New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseases Sosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties Tokyo, Japan and Cambridge, UK, 2 August 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G prote…

Marking its 20th global recipient, the grant program supports next-generation sequencing-based research to explore new and expanded applications for molecular testing CARLSBAD, Calif., August 01, 2022 - As part of its continued commitment to expand the benefits of next-generation sequencing (NGS), Thermo Fisher Scientific is now accepting submissions for the fifth round of the Oncomine Clinical Research Grant program. The program supports clinical and translational research that advances the use of genomic testing to unlock the promise of precision medicine for more cancer patients. The program awards independent clinical research teams with financial support worth up to $200,000 in reagents and general funding. Since its introduction in 2020, the Oncomine Clinical Research Grant program…

Research team ‘EDC’ will study ‘Extrachromosomal DNA in Cancer’. With this project, the two partners launch their ninth collaboration, seven of which have been in the field of oncology. Heidelberg, August 1, 2022. BioMed X, a German independent research institute, announces the start of its new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and thereby trace back the mechanisms of ecDNA formation and function. Like the name suggests, extrachromosomal DNA refers to DNA sequences that are not located on chromosomes. Moreover, cancer-associated extrachromosomal DNA usually contains oncog…

Clinical Development Business to be a Leading, Pure-Play Contract Research Organization with a Comprehensive Set of Clinical Trial Management, Market Access and Technology Capabilities Labcorp Remains a Leader in the Laboratory Market with Highly Complementary, Laboratory-Focused Businesses including Routine and Esoteric Labs, Central Labs and Early Development Research Labs Transaction Designed to Create Value Through Enhanced Strategic and Operational Focus Labcorp to Discuss Spin-off and Second Quarter 2022 Financial Results at 9:00 a.m. ET Today BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2022-- Labcorp (NYSE: LH) (the “Company”), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly…

TARRYTOWN, N.Y., July 26, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students. Each year, Regeneron invites the country's leading research universities to nominate early career scientists. Applicants present their "dream projects" within the field of biomedical science to a committee of Regeneron scientists and leaders, describing and designing the research they would pursue if they had access to any resource or technology, to compete for the Regeneron Prize and an award of $50,000. This year's winners are Ryan Emenecker, Ph.D., of Washington Univer…

The advanced tools and technologies enable improved flexibility and productivity for diagnostics development and support advanced allergy and autoimmune testing and drug monitoring CHICAGO, July 25, 2022 - AACC 2022 Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics. During the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), being held at the McCormick Place Convention Center in Chicago, July 2428, Thermo Fisher is exhibiting within booth #1413. "Our latest platform and workflow innovations give clinical laboratories and researchers greater flexibility and assurance as…

Receives Designation as a Best Place to Work for Disability Inclusion BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 22, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace. The DEI, a joint initiative by Disability:IN® and the American Association of People with Disabilities (AAPD), exists to help businesses make a positive impact on the unemployment and underemployment of people with disabilities. With its score, Labcorp was also designated as a Best Place to Work for Disability Inclusion. The DEI is scored on six categories: Culture & Leadership, Enterprise-Wide Access, Employment P…

Collaboration to kick off at “The Power of a Dream” National Convention in Orlando, Fla. to bridge professional diversity gaps to emphasize importance of health equity for communities of color PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb NYSE (BMY) announced the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement. The strategic alliance is an extension of BMS’ Tomorrow’s Innovators Historically Black College (HBCU) initiative launched with the goal of creating a sustainable bridge of talent to the biopharm…

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company's vision of creating a healthier world for all people. This donation builds on the endowment Gilead announced last year to recapitalize the Gilead Foundation, with a new vision and mission to create impact in the community and society by encouraging a culture of giving, engaging in local communities and exploring innovative approaches to complex social issues. “Our additional contribution to the Gilead Foundation demonstrates our continued commitment to supporting communities and advancing health equity,” said Andrew Dickinson, Chief Financial Officer, Gilead Sciences and Director, Gilead Foundation. “We are proud to dedicat…

GERMANTOWN, Md., July 19, 2022 /PRNewswire/ -- Deka Biosciences announced today that it is breaking ground on a 14,000 square foot office and lab which will house a state of the art Research and Development, Process Development, and Manufacturing facility to further develop their novel cytokine therapies. This will be the first facility to house a dual targeted cytokine development lab in the DC/Maryland/Virginia region and the only company in the US developing a therapeutic of its kind. The new headquarters will be located at 20380 Seneca Meadows Parkway in Germantown, Maryland and Deka anticipates the move to be completed in the first quarter of 2023. "Our new facility will provide us with essential space to expand our research, development and manufacturing efforts, allowing us to conti…

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status. The Elecsys HCV Duo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission. Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. This means that the test can be u…

GSK plc (LSE/NYSE: GSK) has today (Monday 18 July 2022) completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. The shares of Haleon plc (ticker "LSE: HLN") will be admitted at 8.00 a.m. today to the Premium Listing segment of the Official List and to trading on the Main Market of the London Stock Exchange (“LSE”). It is expected that American Depositary Shares representing shares of Haleon plc (ticker: “NYSE: HLN”) (“Haleon ADSs”) will commence “regular-way” trading on the New York Stock Exchange (the “NYSE”) at market open on Friday 22 July 2022. In addition, we expect that Haleon ADSs will begin trading on a “when-issued” basis on the NYSE from market open today up to and including Thursday 21 July 2022. Each Haleon ADS represents two Ha…

Orion to receive an upfront payment of USD 290 million Agreement strengthens and complements Merck’s oncology pipeline RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Orion Corporation (“Orion”) today announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the agreement, Orion and Merck, acting through its subsidiary, Merck Sharp & Dohme LLC, will co-develop a…

Test Measures Key Biomarker Associated with Neuronal Damage; Assists in Diagnosis of Diseases Including Multiple Sclerosis, Alzheimer’s, Parkinson’s and Concussions BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 13, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury. The new Neurofilament Light Chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal injury, whether from diseases like multiple sclerosis, Alzheimer’s and Parkinson’s, or from brain injury, such as wi…

CRO gains access to genetic testing data, aims to improve global research with enhanced data insights and faster patient recruitment for rare disease studies Research Triangle Park, N.C. – July 12, 2022 –Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), today announced its strategic partnership with Invitae, a leading medical genetics company. The partnership makes Worldwide the first CRO to use Invitae’s Explorer tool – part of its real-world data platform that enables access to aggregated genetic testing results. Around the world, 300 million people have a rare disease, and 72 percent of those diseases have genetic origins (source). This partnership underscores Worldwide’s global leadership in rare dise…

BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 11, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced it has formed a strategic partnership with MD Anderson Cancer Center Foundation Spain, a non-profit organization whose objectives are to beat cancer and to increase accessibility of early phase oncology clinical trials. Through this collaboration, oncology clinical trials managed by Labcorp Drug Development will be prioritized and conducted at MD Anderson Cancer Center Foundation Spain, representing a new model for future trials. “This collaboration will help accelerate the discovery and development of cancer therapies worldwide,” said Prasanth Reddy, M.D., MPH, FACP, senior vice president and oncology head at Labcorp. “Early phase clinical research in people with…

ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets ViaCyte to be acquired for $320 million in cash BOSTON--(BUSINESS WIRE)--Jul. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash. “VX-880 has successfully demonstrated clinical proof of concept in T1D, and the acquisition of ViaCyte will accelerate our goal of transforming, if not curing T1D by expanding our capab…